Choose License Type
The demand for G-Protein Coupled Receptors is predicted to show lucrative growth in coming years. The wide use of techniques such as High-Throughput Screening (HTS), combinatorial chemistry and clinical medicine has resulted in the discovery of ligands that modulate the behavior of the target. This, in essence, has resulted in the efficient detection of drug candidates that are pharmaceutically important, which drives the implementation of these receptors in the processes of drug development. In clinical and preclinical trials, the presence of large numbers of licensed medicines and drugs targeting these receptors raises the need for GPCR screening assays in drug production.
In addition, growing government support for drug research and manufacturing programmes in the area of R&D is projected to fuel business demand. In addition, the functional and systemic literature on the pharmacological elements of the GPCRs shows the adaptable advantages of targets of GPCRs in the treatment of an expansive spectrum of conditions that helps extend the market. The high cost of sustaining GPCR cell lines impedes the development of the overall market.
Cancer research dominated the global market and is likely to show steady growth in coming years. Major revenues are generated by the introduction of GPCR assays in oncology research studies. Numerous studies have shown that in cancer patients, the activity of GPCR shows tumour expansion, invasiveness, angiogenesis, metastasis, and drug resistance. Each form of cancer cell/tumor is known to convey a particular collection of GPCR, as per the analysis. It's also been found that certain cell types express >150 different GPCRs, of which one is generated at a comparatively high frequency.
This reinforces the sector's biomarker-based testing, contributing to the creation of the lead candidate targeting GPCRs. In the field of inflammation science, the function of this receptor has developed in recent years. The signaling pathways are regulated by G-protein coupled receptor kinases, such as the nuclear factor x-B signaling pathway, which is linked to various inflammatory processes. Thus, in different inflammatory disorders, these signaling pathways serve as a possible therapeutic target.
The aim of the report is to estimate the size of the market for G-Protein coupled receptors and the future growth potential of the market for G-Protein coupled receptors across various segments, such as patient position and component. The base year considered for the analysis is 2019 and from forecast is provided from 2020-2028.
North America is predicted to lead the global market and is expected to preserve its position over the forecast period. Factors such as strategic investments in cancer research, approvals of GPCR-targeted medicines, and expanded focus on drug discovery & growth activities are key reasons for regional market dominance. 134 GPCR drug targets were accepted in the U.S. or European Union in November 2017 and 128 targets were reported in the orange FDA book.
Key vendors in the market include Abcam PLC, Becton, Dickinson and Company, PerkinElmer Inc., Merck KGaA, Enzo Biochem Inc., Danaher Corporation, Promega Corporation, Bioinvenu Corporation, Thermo Fisher Scientific Inc, and many more. The core approaches pursued by these businesses for retaining their market position are mergers, acquisitions, and licensing agreements for R&D activities. In addition, they are combining robotics and emerging technology with screening protocols for drug discovery to enhance their therapeutic manufacturing capability.
Key Segments of the Global G-Protein Coupled Receptors Market
Product Overview, 2018-2028 (USD Million)
Assay Type Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global G-Protein Coupled Receptors Market
Reasons for the study
What does the report include?
Who should buy this report?
The demand for G-Protein Coupled Receptors is predicted to show lucrative growth in coming years. The wide use of techniques such as High-Throughput Screening (HTS), combinatorial chemistry and clinical medicine has resulted in the discovery of ligands that modulate the behavior of the target. This, in essence, has resulted in the efficient detection of drug candidates that are pharmaceutically important, which drives the implementation of these receptors in the processes of drug development. In clinical and preclinical trials, the presence of large numbers of licensed medicines and drugs targeting these receptors raises the need for GPCR screening assays in drug production.
In addition, growing government support for drug research and manufacturing programmes in the area of R&D is projected to fuel business demand. In addition, the functional and systemic literature on the pharmacological elements of the GPCRs shows the adaptable advantages of targets of GPCRs in the treatment of an expansive spectrum of conditions that helps extend the market. The high cost of sustaining GPCR cell lines impedes the development of the overall market.
Cancer research dominated the global market and is likely to show steady growth in coming years. Major revenues are generated by the introduction of GPCR assays in oncology research studies. Numerous studies have shown that in cancer patients, the activity of GPCR shows tumour expansion, invasiveness, angiogenesis, metastasis, and drug resistance. Each form of cancer cell/tumor is known to convey a particular collection of GPCR, as per the analysis. It's also been found that certain cell types express >150 different GPCRs, of which one is generated at a comparatively high frequency.
This reinforces the sector's biomarker-based testing, contributing to the creation of the lead candidate targeting GPCRs. In the field of inflammation science, the function of this receptor has developed in recent years. The signaling pathways are regulated by G-protein coupled receptor kinases, such as the nuclear factor x-B signaling pathway, which is linked to various inflammatory processes. Thus, in different inflammatory disorders, these signaling pathways serve as a possible therapeutic target.
The aim of the report is to estimate the size of the market for G-Protein coupled receptors and the future growth potential of the market for G-Protein coupled receptors across various segments, such as patient position and component. The base year considered for the analysis is 2019 and from forecast is provided from 2020-2028.
North America is predicted to lead the global market and is expected to preserve its position over the forecast period. Factors such as strategic investments in cancer research, approvals of GPCR-targeted medicines, and expanded focus on drug discovery & growth activities are key reasons for regional market dominance. 134 GPCR drug targets were accepted in the U.S. or European Union in November 2017 and 128 targets were reported in the orange FDA book.
Key vendors in the market include Abcam PLC, Becton, Dickinson and Company, PerkinElmer Inc., Merck KGaA, Enzo Biochem Inc., Danaher Corporation, Promega Corporation, Bioinvenu Corporation, Thermo Fisher Scientific Inc, and many more. The core approaches pursued by these businesses for retaining their market position are mergers, acquisitions, and licensing agreements for R&D activities. In addition, they are combining robotics and emerging technology with screening protocols for drug discovery to enhance their therapeutic manufacturing capability.
Key Segments of the Global G-Protein Coupled Receptors Market
Product Overview, 2018-2028 (USD Million)
Assay Type Overview, 2018-2028 (USD Million)
Application Overview, 2018-2028 (USD Million)
Regional Overview, 2018-2028 (USD Million)
Important Companies in Global G-Protein Coupled Receptors Market
Reasons for the study
What does the report include?
Who should buy this report?
1. Introduction
1.1. Introduction to the Study
1.2. Market Definition and Scope
1.3. Units, Currency, Conversions and Years Considered
1.4. Key Stakeholders
1.5. Key Questions Answered
2. Research Methodology
2.1. Introduction
2.2. Data Capture Sources
2.3. Market Size Estimation
2.4. Market Forecast
2.5. Data Triangulation
2.6. Assumptions and Limitations
3. Market Outlook
3.1. Introduction
3.2. Macroeconomic Indicators
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Restraints/Challenges
3.3.3. Opportunities
3.4. Porter’s Five Forces Analysis
3.5. COVID-19 impact analysis
4. Global G-Protein Coupled Receptors Market by Product, 2018-2028 (USD Million)
4.1. Cell Lines
4.2. Detection Kits
4.3. Cell Culture Reagents
4.4. Ligands
5. Global G-Protein Coupled Receptors Market by Assay Type, 2018-2028 (USD Million)
5.1. cAMP Functional Assays
5.2. Calcium Functional Assays
5.3. β-Arrestin Functional Assays
5.4. Radioligand Binding and GTPγS Functional Assays
5.5. Internalization Assays
5.6. Trafficking Assays
5.7. Other Assays
6. Global G-Protein Coupled Receptors Market by Application, 2018-2028 (USD Million)
6.1. Cardiovascular Research
6.2. Inflammation Research
6.3. Cancer Research
6.4. CNS Research
6.5. Metabolic Research
6.6. Respiratory Research
6.7. Other Applications
7. Global G-Protein Coupled Receptors Market by Region, 2018-2028 (USD Million)
7.1. North America
7.1.1. U.S.
7.1.2. Canada
7.2. Europe
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Rest of Europe
7.3. Asia Pacific
7.3.1. China
7.3.2. Japan
7.3.3. India
7.3.4. Rest of Asia Pacific
7.4. Latin America
7.4.1. Brazil
7.4.2. Mexico
7.4.3. Rest of Latin America
7.5. Middle East & Africa
8. Competitive Landscape
8.1. Company Positioning
8.2. Strategic Initiatives
8.2.1. Mergers & Acquisitions
8.2.2. New Product Launch
8.2.3. Investments
8.2.4. Expansion
8.2.5. Others
9. Company Profiles
(Overview, Products and Services Portfolio, Recent Initiatives, Company Financials)
9.1. Abcam PLC
9.2. Becton, Dickinson and Company
9.3. PerkinElmer Inc.
9.4. Merck KGaA
9.5. Enzo Biochem Inc. (Enzo Life Sciences Inc.)
9.6. Danaher Corporation (Molecular Devices LLC)
9.7. Promega Corporation
9.8. Bioinvenu Corporation
9.9. Thermo Fisher Scientific Inc
9.10. Eurofins Scientific
10. Appendix
10.1. Primary Research Approach
10.1.1. Primary Interview Participants
10.1.2. Questionnaire
10.2. Related Reports
10.2.1. Published
10.2.2. Upcoming